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ABSTRACT
Introduction Despite increasing evidence of its efﬁcacy
in advanced age or in mild or severe strokes, intravenous
thrombolysis remains underused for acute ischaemic
stroke (AIS). Our aim was to obtain an updated view of
reasons for non-thrombolysis and to identify its changing
patterns over time.
Methods This is a retrospective study of prospectively
collected data from the Acute Stroke Registry and
Analysis of Lausanne (ASTRAL) from the years 2003–
2011. Patients admitted with acute stroke in the past
24 hours who had not had thrombolysis were identiﬁed;
reasons for non-thrombolysis documented in the
prospectively entered data were tabulated and analysed
for the group as a whole. Data were analysed for the
years 2003–2006 and 2007 forward because of
changes in contraindications. A subgroup of patients
who arrived within the treatment window ≤180 min
was separately analysed for reasons for non-
thrombolysis. Predictors of non-thrombolysis were
investigated via multivariate regression analyses.
Results In the 2019 non-thrombolysed patients the
most frequent reasons for non-thrombolysis were
admission delays (66.3%), stroke severity (mostly mild)
(47.9%) and advanced age (14.1%); 55.9% had more
than one exclusion criterion. Among patients arriving
≤180 min after onset, the main reasons were stroke
severity and advanced age. After 2006, signiﬁcantly
fewer patients were excluded because of age (OR 2.65,
p<0.001) or (mostly mild) stroke severity (OR 10.56,
p=0.029). Retrospectively, 18.7% of all non-
thrombolysed patients could have been treated because
they only had relative contraindications.
Conclusion Onset-to-admission delays remain the
main exclusion criterion for thrombolysis. Among early
arrivals, relative contraindications such as minor stroke
severity and advanced age were frequent. Thrombolysis
rate increased with the reduction of thrombolysis
restrictions (eg, age and stroke severity).
INTRODUCTION
Intravenous thrombolysis with recombinant tissue
plasminogen activator (rt-PA) administered within
4.5 hours from onset of stroke symptoms improves
the clinical outcome of patients with acute ischae-
mic stroke (AIS).1–4 Some early arrival patients are
not treated with rt-PA because of exclusion criteria
that were previously based on exclusions from the
initial thrombolysis trials.5 Further randomised
trials6 and analyses from subgroups of trials7 and
large case series have since suggested early thromb-
olysis is indicated even in advanced age,8 9 in both
mild and high stroke severity and with rapidly
improving symptoms.10–13 One prominent reason
for non-thrombolysis is time delay.14 15 Although
very early thrombolysis remains a major goal in
acute stroke care, there is now scientiﬁc evidence
that intravenous thrombolysis is effective up to
4.5 hours.2 4 With respect to relative and absolute
contraindications for intravenous thrombolysis, our
aim was to obtain the frequency and reasons for
non-thrombolysis and how these have changes over
time.
METHODS
This was a retrospective analysis of the Acute
STroke Registry and Analysis of Lausanne
(ASTRAL). As described previously,16 data of all
patients with AIS admitted to the stroke unit
and/or intensive care unit at the Centre Hospitalier
Univeristaire Vaudois (CHUV), Switzerland,
between 2003 and 2011 were collected in a
pre-speciﬁed manner at the time of patient presen-
tation. Demographic data, onset-to-door-time,
Key messages
What is already known on this subject?
Thrombolysis with recombinant tissue plasminogen
activator (rt-PA) is standard therapy for patients
with acute ischaemic stroke in the ﬁrst 4.5 hours
after stroke onset. Some contraindications deﬁned
at the introduction of thrombolysis with rt-PA for
ischaemic stroke have not shown be increase the
risk for patients. Therefore, most such patients
should also be treated with thrombolysis and
reasons for not being thrombolysed are of major
interest in improving thrombolysis rates.
What this study adds?
In this study using prospectively collected data
from a large, single centre Swiss stroke database,
we found that the primary reason for non-
thrombolysis was delay in presentation. About
20% of patients who arrived within the
appropriate timeframe were not thrombolysed due
to only relative contraindications. Growing
evidence about safety of thrombolysis in those
certain patient groups may lead to higher
thrombolysis rates. Finally, given that onset-to-
admission delays remain the main exclusion
criterion for thrombolysis, we could corroborate
the urgent need for further optimising stroke
recognition and pre-hospital systems of care by
educating the population and (para)medical
personnel about the paramount importance of
time in suspected stroke.
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known or newly diagnosed vascular risk factors (arterial hyper-
tension, atrial ﬁbrillation, diabetes mellitus, valve replacements,
coronary artery disease, smoking, etc) and previous cerebrovas-
cular events were recorded. Stroke pathophysiology was classi-
ﬁed according to the Trial of Org 10172 in Acute Stroke
Treatment17 classiﬁcation, with four classes added (cervical
artery dissections, likely atherosclerosis without signiﬁcant sten-
osis,18 multiple mechanisms and probable relation to a patent
foramen ovale). Stroke severity on arrival was recorded with the
National Institute of Health Stroke Scale (NIHSS) score per-
formed or supervised by certiﬁed medical personnel. Relevant
data such as demographics, initial NIHSS score, onset-
to-admission delays, acute recanalisation treatment and reasons
for non-thrombolysis were completely available because the
registry forces the user to complete these ﬁelds.
Thrombolysis and stroke management of ASTRAL patients
and the written in-hospital thrombolysis guidelines are in line
with European Stroke Organisation (ESO)19 and Swiss recom-
mendations20 and are adapted regularly to take account of
evidence-based publications.2 21 22 Detailed reasons for non-
thrombolysis are pre-speciﬁed in ASTRAL and collected in six
domains: time delays, initial stroke severity, age, imaging, high
bleeding risk and other reasons. The detailed reasons for each
domain with modiﬁcations over time are listed in table 1. In the
whole observation period, thrombolysis contraindications were
classiﬁed as absolute or relative (table 1). Further absolute con-
traindications such as acute pancreatitis, bacterial endocarditis,
pericarditis, oesophageal varices, ulcerative gastrointestinal
disease or neoplasms with acute bleeding risk are not explicitly
listed but were considered in the database. Reasons for non-
thrombolysis could be singular or multiple. The absence of any
good reasons against intravenous thrombolysis according to the
current hospital recommendations (a ‘missed’ thrombolysis
opportunity) was explicitly documented at the time of entering
the data in ASTRAL, that is, during the acute hospital stay of
the patient. Using the ASTRAL registry, consecutive patients
with AIS admitted to the stroke unit and/or intensive care unit
at the CHUV between 2003 and 2011 within 24 hours of the
last proof of good health were retrospectively analysed for the
reasons why they did not receive intravenous rt-PA treatment.
Since delayed presentation was likely to be an important factor in
those presenting outside the treatment window, we also com-
pared the reasons for non-thrombolysis between those presenting
within the early treatment window and those presenting later.
Because the response to thrombolysis becomes minor beyond
3 hours and even less beyond 4.5 hours,23 we chose 180 min as
the latest cut-off, considering that patients could not be thrombo-
lysed beyond this delay before 2008 and allowing for some
in-hospital time thereafter. Additionally, we compared the fre-
quency and reasons for non-thrombolysis during the ﬁrst (2003–
2006) versus the second (2007–2011) half of the observation
period to identify changes in thrombolysis implementation and
decision-making over time. The 2006 cut-off was chosen in
order to obtain two cohorts of comparable size which maximised
the power of the statistical analysis to identify true differences
between the two time periods. Sample size was based on the
Table 1 Contraindications for thrombolysis in our centre, with changes over time (some further softening of contraindications took place since
end of data collection for this analysis)
Domain Contraindication Change over time
Time delays Thrombolysis time window >180 min Thrombolysis time window >270 min since
November 2008
Thrombolysis time window >180 min and no indication for intra-arterial treatment within 6 hours
(‘too late intravenous and no indication intra-arterial’)
–
Unknown stroke onset and inability to treat within recommended time limits since last proof of
good health
–
Initial stroke severity * Too mild: NIHSS <6 NIHSS <4, unless hemianopia or aphasia since
October 2006
* Too severe: NIHSS >25 No upper NIHSS-limit since October 2006
* Any ‘rapid improvement’ (not quantified) Rapid improvement reaching NIHSS <4 since
September 2006
Age limit * >80 years No age limit since October 2006, unless
significant pre-existing disability
Imaging
contraindications
Plain cCT: >30% hypo-attenuation of MCA territory –
In borderline indications: large core on acute perfusion CT and/or little salvageable tissue –
Large subacute (silent) infarction on imaging, defined as a poorly demarcated, hypodense
territorial lesion with mild local swelling or absence of the usual atrophy of chronic stroke lesions
–
Acute intracranial haemorrhage –
High bleeding risk INR >1.2 INR >1.5 since October 2006
Thrombocytopenia <100 000/mm3 –
Recent surgical intervention <14 days –
Previous intracranial haemorrhage –
Intracranial vascular malformation (known or suspected on plain cCT) –
Full dose heparin or LMWH –
Other bleeding risk –
Other reasons No good reason (thrombolysis opportunity missed) –
Recent ischaemic stroke or brain trauma <3 months –
Stroke diagnosis uncertain –
* Concomitant epileptic seizure Thrombolysis indicated, if imaging confirmed
acute ischaemic stroke since 9/2006
* Comorbidity, severely limiting life expectancy, or pre-stroke dependency, defined as mRS >2 –
Asterisk (*) indicates a relative contraindication.
cCT, cranial CT; INR, international normalised ratio; LMWH, low molecular weight heparin; MCA, middle cerebral artery; mRS, modified Rankin Scale; NIHSS, National Institute of Health
Stroke Scale score.
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number of patients in the registry. The anonymised use of
ASTRAL data for scientiﬁc purposes without the need for indi-
vidual consent was approved by the Ethics Committee for
Research on Humans of the canton of Vaud, sub-commission III.
Statistical analysis
We calculated the proportion of patients not receiving thromboly-
sis for the entire period and for the time periods between
2003–2006 and 2007–2011. Descriptive statistics of non-
thrombolysed and thrombolysed patients (baseline characteristics/
mechanisms of stroke) and of the most common reasons for non-
thrombolysis are presented. Patients arriving before and after
180 min and patients with admission during the ﬁrst (2003–2006)
versus the second (2007–2011) half of the observation period
were compared using a logistic regression model that included
potential predictor variables (age, sex, NIHSS score at admission,
risk factors, stroke mechanism, time/severity/imaging/bleeding/
other reasons for non-thrombolysis). The OR and its 95% CI or
its associated p values were given to quantify and test the signiﬁ-
cance of the strength of the association. Predictors with p<10%
in bivariate analysis were used to ﬁt a multivariate logistic model.
P Values of 0.683 (table 2) and 0.469 (table 3) in
Hosmer-Lemeshow goodness-of-ﬁt test suggested that each model
ﬁtted reasonably well. Analyses were conducted with STATA/IC
(V.13.0; College Station, Texas, USA).
RESULTS
Patient population
Over the 9-year observation period, 599 of 2618 patients with
AIS (22.9%) in ASTRAL received thrombolysis. The annual
thrombolysis rate increased from 9.7% in 2003 to 33.6% in
2011. Among all thrombolysed patients, 27.5% were thrombo-
lysed between 2003 and 2006 and 72.5% were thrombolysed
between 2007 and 2011. The median age of non-thrombolysed
patients was 73 (IQR 61, 82); admission NIHSS score was 4.5
(IQR 2, 10), whereas the median age of those thrombolysed was
69 (IQR 58, 78) and median NIHSS score was 13 (IQR 8, 19,
table 4). Among both thrombolysed and non-thrombolysed
patients, cardioembolism was the most common aetiology of the
stroke. Non-thrombolysed patients had less cardioembolic
strokes respectively more microangiopathic aetiology than
thrombolysed patients (see online supplementary table S1).
Further baseline characteristics of thrombolysed and non-
thrombolysed patients are listed in table 4. During the study
period, the number of endovascular recanalisation treatments
(mostly combined intravenous and mechanical thrombectomy)
Table 2 Reason for non-thrombolysis. Multivariate analysis of reasons for non-thrombolysis divided by onset-to-admission delay
(≤180 min vs >180 min)
Patients (n=2019) ≤180 min (n=659) >180 min (n=1360) OR p Value 95% CI
Too mild stroke 323 (49%) 567 (42%) 3.35* 0.000 1.82 to 6.18
Age >80 years 112 (17%) 164 (12%) 2.98* 0.007 1.36 to 6.56
Other bleeding reasons 15 (2%) 9 (1%) 10.12* 0.026 1.33 to 77.23
Recent stroke (clinically or radiologically) <3 months 36 (6%) 13 (1%) 4.50 0.071 0.88 to 23.01
Other reasons 16 (2%) 8 (1%) 13.77* 0.033 1.23 to 153.68
Microangiopathic stroke mechanism 75 (11%) 233 (17%) 0.28* 0.010 0.11 to 0.74
Other determined or rare stroke mechanism 54 (8%) 32 (2%) 3.48 0.096 0.80 to 15.08
Atrial fibrillation 179 (27%) 287 (21%) 1.94* 0.034 1.05 to 3.58
Mechanical or biological heart valves 23 (4%) 40 (3%) 3.62* 0.049 1.01 to 13.01
OR >1 means more likely ≤180 min and <1 means more likely >180 min.
Asterisk (*), significant on p<0.05 level. Definitions of reasons for non-thrombolysis see text/table 5.
Table 3 Multivariate analysis of reasons for non-thrombolysis comparing the first (n=959) with the second (n=1060) half of the observation
period
Patients (n=2019) 2003–2006 2006–2011 OR p Value 95% CI
Too late intravenous and no indication intra-arterial 127 (13%) 76 (7%) 1.79* 0.010 1.15 to 2.78
Unknown onset 268 (28%) 399 (38%) 0.69* 0.008 0.53 to 0.91
Too mild stroke 442 (46%) 497 (47%) 0.66* 0.002 0.51 to 0.86
Too severe stroke 20 (2%) 5 (1%) 10.56* 0.029 1.28 to 87.42
Rapid improvement to below threshold 16 (2%) 2 (0.2%) 5.43 0.109 0.69 to 43.01
Age >80 years 183 (19%) 102 (10%) 2.65* 0.000 1.76 to 3.99
Intracranial haemorrhage 3 (0.3%) 20 (2%) 0.11* 0.004 0.02 to 0.50
Other bleeding reasons 3 (0.3%) 21 (2%) 0.18* 0.020 0.04 to 0.77
Stroke uncertain 10 (1%) 48 (5%) 0.19* 0.000 0.08 to 0.44
Comorbidity/dependency 21 (2%) 64 (6%) 0.16* 0.000 0.09 to 0.31
Diabetes mellitus 132 (14%) 200 (19%) 0.53* 0.000 0.39 to 0.72
Hyperlipidaemia 589 (61%) 707 (67%) 0.53* 0.000 0.40 to 0.70
Probable atherosclerotic stroke mechanism (<50% stenosis) 151 (16%) 152 (14%) 1.50* 0.023 1.06 to 2.11
Microangiopathic stroke mechanism 171 (18%) 149 (14%) 1.72* 0.002 1.21 to 2.43
OR >1 means more likely in first half and <1 means more likely in second half of observation period.
Asterisk (*), significant on p<0.05 level. Definitions of reasons for non-thrombolysis see text/table 5.
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remained minor thrombolysis and reached 5/98 patients (5.1%)
in 2011. Yearly thrombolysis rates are set out in ﬁgure 1. Stroke
aetiology of the 2019 non-thrombolysed and 599 thrombolysed
patients is shown in online supplementary table S1.
Relative contraindications
A total of 321 of all non-thrombolysed patients (15.9%) had
only relative contraindications to thrombolysis as deﬁned in
table 1. Of these, 283 patients (14.0%) had only one and 38
(1.9%) had multiple relative contraindications. About 57
patients (2.8%) had clearly been overlooked as candidates for
thrombolysis by the physician not performing the thrombolysis
when compared with the current hospital recommendations at
the time.
Reasons for non-thrombolysis of patients
The most frequent causes for exclusion of thrombolysis among
all patients were onset-to-admission delays (often including
wake-up strokes), which were found in 66.3% of non-
thrombolysed patients followed by mild strokes (45.8%),
according to the hospital guidelines at the time (table 5). A total
of 1128 patients (55.9%) had more than only one reason for
exclusion.
Reasons for non-thrombolysis for those within the early
therapeutic window
The median age of non-thrombolysed patients treated ≤180 min
was 73 (IQR 61, 82), admission NIHSS score was 4.5 (IQR 2,
11) and main stroke aetiology was cardioembolic (30.8%) fol-
lowed by macroangiopathic stroke without signiﬁcant stenosis18
(13.5%) and macroangiopathic stroke with ≥50% stenosis
(13.2%), whereas the median age of those treated >180 min
was 73 (IQR 60, 82), median NIHSS score was 5 (IQR 2, 10)
and main stroke aetiology was cardioembolic (26.1%) followed
by microangiopathic stroke (17.1%) and macroangiopathic
stroke without signiﬁcant stenosis (14.9%). The bivariate ana-
lysis of patients treated ≤180 min versus >180 min after stroke
onset is shown in table 6; signiﬁcantly more patients in the early
group had severity reasons for exclusion (mostly too mild
strokes), were aged > 80 years, had higher bleeding risks and
had other reasons like recent stroke or pre-stroke comorbidity/
dependency. In the multivariate analysis of early (≤180 min)
versus late arriving non-thrombolysed patients, those in the
early group signiﬁcantly had more mild strokes, were aged
>80 years, had high bleeding risk and had atrial ﬁbrillation
(table 2). Among patients admitted early, reasons for not being
thrombolysed were more often a combination of different
reasons rather than one single reason alone.
Change over time
The median age of non-thrombolysed patients treated in
2003–2006 was 73 (IQR 60, 81); admission NIHSS score was
5 (IQR 3, 12) and main stroke aetiology was cardioembolic
(28.9%) followed by microangiopathic stroke (17.8%) and
macroangiopathic stroke without signiﬁcant stenosis (15.7%),
whereas the median age of those treated in 2007–2011 was 74
(IQR 61, 83); median NIHSS score was 4 (IQR 2, 9) and main
Figure 1 Rates of thrombolysed patients per year (n=2618).
Table 4 Baseline characteristics of non-thrombolysed and thrombolysed patients. Continuous variables are given as medians with IQR (lower
and upper quartiles) and as n (%) for categorical variables
Non-thrombolysed patients (n=2019) Thrombolysed patients (n=599)
n or median % or quartiles n or median % or quartiles
Age (years) 73 61, 82 69 58, 78
Sex (male) 1131 56.0% 349 58.3%
Onset-to-door time (min) 337 125, 774 93 58, 135.5
Onset to admission ≤180 min 659 32.6% 523 87.3%
Admission NIHSS 4.5 2, 10 13 8, 19
Treated in first observation period (2003–2006) 959 47.5% 173 28.9%
Hypertension 1317 65.2% 346 57.8%
Hyperlipidaemia 1296 64.2% 362 60.4%
Atrial fibrillation 488 24.2% 156 26.0%
Active smoking 434 21.5% 136 22.7%
Diabetes mellitus 332 16.4% 97 16.2%
Symptomatic coronary artery disease* 295 14.6% 85 14.2%
Symptomatic peripheral artery disease 106 5.3% 23 3.8%
Low ejection fraction (<35%) 84 4.2% 34 5.7%
Cancer not in remission 77 3.8% 14 2.3%
Heart valves 64 3.2% 10 1.7%
*Documented by myocardial infarct diagnosis, coronarography or stress test.
NIHSS, National Institute of Health Stroke Scale score.
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stroke aetiology was cardioembolic (28.4%) followed by macro-
angiopathic stroke without signiﬁcant stenosis (14.3%) and
microangiopathic stroke (14.1%). Most frequently, time reasons
were a cause for not being thrombolysed, showing signiﬁcantly
more patients with unknown stroke onset in the group treated
2007–2011 followed by severity reasons, showing signiﬁcantly
more patients with too severe stroke or rapid improvement of
stroke symptoms in the group treated 2003–2006 (table 7).
More patients treated in 2003–2006 were excluded from
thrombolysis than in 2007–2011 (86.7% vs 73.5%). Of those
378 non-thrombolysed patients who had no (or only relative)
contraindications, 204 (54%) were treated in the earlier period
and 174 (46%) in the later period. After distraction of patients
thrombolysed in the extended time window of 3–4.5 hours after
October 2008, there was still an increase in the number of
thrombolysed patients in the later time period (ﬁgure 1).
Compared with the 2007 onward group (multivariate analysis,
table 3), in the 2003–2006 group, signiﬁcantly more patients
were excluded because they were thought to be too severely
affected, their age was >80 years, they had rapid neurological
improvement or they were too late arriving. After 2006 (when
older patients and later-arriving patients could be thrombo-
lysed), signiﬁcantly more patients were excluded because of
unknown stroke onset, too mild stroke, comorbidity or depend-
ency, unrecognised stroke, increased bleeding risk, imaging
reasons and intracranial haemorrhage. Also more patients had
diabetes and hyperlipidaemia, while fewer patients had microan-
giopathic strokes.
DISCUSSION
Using a consecutive single-centre series of patients with AIS
having detailed pre-speciﬁed recording of reasons for non-
thrombolysis over a period of 9 years, we found time delays to
be the main reason. We also found a remarkable number of
patients excluded from thrombolysis on account of one single
relative contraindication—mild stroke symptoms being the most
frequent cause in all patients and in early arrivals.
The thrombolysis rate increased over time because fewer
restrictions related to age, stroke severity, comorbidities or other
relative contraindications were applied and the time window
was increased from 3 to 4.5 hours in November 2008, leading
to fewer patients excluded because of arriving too late. Long
pre-hospital time delays underline the importance of improving
stroke recognition via continuous public awareness campaigns
and use of simpliﬁed pre-hospital stroke scales (eg, FASTER
protocol24) by dispatchers and paramedics. Furthermore, triage,
routines of pre-notiﬁcation of specialised hospitals and diagnosis
by telemedicine approaches could optimise pre-hospital patient
ﬂow.25–29 A signiﬁcant number of patients (especially those with
wake-up strokes) would also beneﬁt from a further extension of
the time window: several such late revascularisation trials are
now in progress.30–32 The relative frequency of reasons for non-
thrombolysis was similar to previously published data,15 33–35
but we found more patients excluded because of advanced age
or unknown stroke onset. The large number of patients
excluded because of unknown stroke onset, especially in the
second observation period, may be due to an increase of such
patients referred to us after our randomised pilot trial on
thrombolysis for unknown stroke onset.36
In the ﬁrst half of the observation period, age >80 years was
a main reason for non-thrombolysis. ‘Too severe stroke’ or rapid
improvement was also found as a reason but, because of low fre-
quencies, did not contribute to the failure of thrombolysis in a
substantial way. In the second half of the observation period,
after the age restriction was removed, ‘too mild stroke’ became
a relatively more frequent reason for non-thrombolysis,
although we lowered our threshold NIHSS score from 6 to 4
and recommended thrombolysis for patients with isolated
aphasia or hemianopia. Signiﬁcantly more patients in the second
observation period were not thrombolysed because of
comorbidities, pre-stroke dependency or bleeding risks, prob-
ably reﬂecting an increasingly fragile stroke population over
time. Many trials now conﬁrm the safety and efﬁcacy of
thrombolytic therapy in patients with too mild stroke symptoms
and in those aged >80 years.9–11 22 23 However, only one of
these trials (International Stroke Trial-36) had a randomised con-
trolled design with pre-speciﬁed subgroup analysis. The main
Table 5 Reasons for not being thrombolysed (n=2019)
Reason: time
Too late intravenous 51 2.5%
Too late intravenous and no indication intra-arterial 203 10.1%
Too late intravenous and intra-arterial 418 20.7%
Unknown onset* 667 33.0%
Total 1339 66.3%
Reason: severity
Too mild† 924 45.8%
Too severe‡ 25 1.2%
Rapid improvement to below threshold 18 0.9%
Total 967 47.9%
Reason: age
>80 years till 2006§ 285 14.1%
Reason: imaging
Too large infarct¶ 32 1.6%
Too little penumbra 12 0.6%
Too large infarct and too little penumbra 7 0.3%
Large subacute infarct on imaging** 18 0.9%
Other/intracranial haemorrhage 23 1.1%
Total 92 4.6%
Reason: high bleeding risk
INR elevated†† 174 8.6%
Thrombocytopenia‡‡ 6 0.3%
Recent intervention 19 0.9%
Previous intracranial haemorrhage 17 0.8%
Intracranial vascular malformation 14 0.7%
Full dose heparin or LMWH 20 1.0%
Other bleeding risk 24 1.2%
Total 274 13.6%
Reason: other
No good reason according to hospital
recommendations (thrombolysis missed)
57 2.8%
Recent stroke§§ 51 2.5%
Stroke uncertain 58 2.9%
Epileptic seizure 13 0.6%
Comorbidity/dependency 85 4.2%
Total 290 14.4%
*>60 min uncertainty and too late for thrombolysis.
†NIHSS <6 until September 2006, NIHSS <4 from October 2006 without isolated
hemianopia or aphasia thereafter.
‡NIHSS>25 till September 2006, no limit thereafter.
§Since October 2006: >80 and significant comorbidity or dependency.
¶Non-contrast image or perfusion image.
**Defined as a poorly demarcated, hypodense territorial lesion with mild local
swelling or absence of the usual atrophy of chronic stroke lesions.
††>1.2 before October 2006 and >1.5 thereafter.
‡‡<100 000/mm3.
§§Clinically or radiologically <3 months.
INR, international normalised ratio; LMWH, low molecular weight heparin; NIHSS,
National Institute of Health Stroke Scale score.
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beneﬁt in this study was seen within the ﬁrst 3 hours. Another
randomised trial focusing on the elderly is in progress
(Thrombolysis in Elderly Stroke Patients in Italy37).
Thrombolysis is also effective in patients with mild stroke symp-
toms38–43 and can be improved by multimodal imaging.44
The strengths of our study are pre-speciﬁed and detailed
documentation of exclusion criteria for thrombolysis. Its limita-
tion is its monocentric character with specialised stroke care,
where a subset of patients with AIS was speciﬁcally referred for
acute recanalisation therapy. Still, 77.8% of the population
examined came from our primary catchment area and most
non-thrombolysed patients came from this area.
CONCLUSIONS
Liberalising criteria for thrombolysis were associated with an
increase in thrombolysis of stroke patients at our centre.
Onset-to-admission delays remain the main exclusion criteria
for thrombolysis, emphasising the need for better pre-hospital
Table 6 Reasons for non-thrombolysis divided by onset-to-admission delay (≤180 min vs >180 min)
Arrival
OR 95% CI≤180 min (n=659) >180 min (n=1360)
Patient characteristics
Age (median quartiles) 73 61, 82 73 60, 82 1.00 0.99 to 1.01
Sex (male) 393 59.6% 699 51.4% 1.24* 1.03 to 1.50
Admission NIHSS (median quartiles) 4.5 2, 11 5 2, 10 1.00 0.99 to 1.00
Stroke mechanism (TOAST)†
Atherosclerosis with ≥50% (NASCET) stenosis 87 13.2% 158 11.6% 1.08 0.82 to 1.43
Likely atherosclerosis/aortic, without significant stenosis‡ 89 13.5% 203 14.9% 0.83 0.63 to 1.08
Cardioembolism 203 30.8% 355 26.1% 1.16 0.95 to 1.43
Small vessel occlusion 75 11.4% 233 17.1% 0.58* 0.44 to 0.76
Dissections 24 3.6% 49 3.6% 0.95 0.58 to 1.56
Other determined 54 8.2% 32 2.4% 3.49* 2.23 to 5.46
Undetermined mechanism 57 8.6% 121 8.9% 0.91 0.65 to 1.26
Multiple mechanisms 39 5.9% 56 4.1% 1.38 0.90 to 2.10
PFO as likely cause 19 2.9% 50 3.7% 0.73 0.43 to 1.25
Reason: severity
Too mild 323 49.0% 567 41.7% 1.22* 1.01 to 1.47
Too severe 12 1.8% 12 0.9% 1.97 0.88 to 4.40
Rapid improvement to below threshold 15 2.3% 3 0.2% 9.94* 2.87 to 34.48
Total 350 53.1% 582 42.8% 1.37* 1.13 to 1.66
Reason: age
>80 years 112 17.0% 164 12.1% 1.40* 1.08 to 1.82
Reason: imaging
Too large infarct 3 0.5% 27 2.0% 0.21* 0.06 to 0.70
Too little penumbra 6 0.9% 6 0.4% 1.96 0.63 to 6.09
Too large infarct and too little penumbra 3 0.5% 3 0.2% 1.95 0.39 to 9.70
Subacute infarct on imaging 12 1.8% 5 0.4% 4.74* 1.66 to 13.52
Other/intracranial haemorrhage 10 1.5% 13 1.0% 1.51 0.66 to 3.45
Total 34 5.2% 54 4.0% 1.24 0.80 to 1.92
Reason: high bleeding risk
INR elevated 71 10.8% 96 7.1% 1.49* 1.08 to 2.06
Thrombocytopenia 2 0.3% 4 0.3% 0.97 0.18 to 5.33
Recent intervention 16 2.4% 3 0.2% 10.62* 3.08 to 36.60
Previous intracranial haemorrhage 10 1.5% 6 0.4% 3.28* 1.19 to 9.07
Intracranial vascular malformation 5 0.8% 9 0.7% 1.08 0.36 to 3.24
Other 15 2.3% 9 0.7% 3.30* 1.44 to 7.58
Full dose heparin or LMWH 17 2.6% 3 0.2% 11.31* 3.30 to 38.72
Total 136 20.6% 130 9.6% 2.31* 1.78 to 3.00
Reason: other
No good reason according to hospital recommendations 45 6.8% 10 0.7% 9.34* 4.68 to 18.66
Recent stroke 36 5.5% 13 1.0% 5.65* 2.98 to 10.73
Stroke uncertain 26 3.9% 29 2.1% 1.78* 1.04 to 3.04
Epileptic seizure 7 1.1% 4 0.3% 3.43* 1.00 to 11.78
Comorbidity/dependency 38 5.8% 43 3.2% 1.77* 1.13 to 2.76
Total 152 23.1% 99 7.3% 3.97* 1.69 to 9.32
Asterisk (*), significant on p<0.05 level. Definitions of reasons for non-thrombolysis see text/table 5.
†TOAST17 classification.
‡Ipsilateral internal carotid stenosis <50%(NASCET)/risk factors for atherosclerotic disease, for details see PERFORM definition.18
INR, International Normalised Ratio; LMWH, low molecular weight heparin; NIHSS, National Institute of Health Stroke Scale score; PFO, patent foramen ovale; TOAST, Trial of Org 10172
in Acute Stroke Treatment.
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Table 7 Reasons for non-thrombolysis comparing the first with the second half of the observation period
Year
Patients (n=2019) 2003–2006 (n=959) 2007–2011 (n=1060) OR 95% CI
Patient characteristics
Age (median quartiles) 73 60, 81 74 61, 83 1.00 0.99 to 1.00
Sex (male) 530 55.3% 601 56.7% 0.94 0.79 to 1.13
Admission NIHSS (median quartiles) 5 3, 12 4 2, 9 1.00* 1.00 to 1.01
Stroke mechanism (TOAST)†
Atherosclerosis with ≥50% (NASCET) stenosis 106 11.1% 147 13.9% 0.73* 0.56 to 0.95
Likely atherosclerosis/aortic, without significant stenosis‡ 151 15.7% 152 14.3% 1.06 0.83 to 1.35
Cardioembolism 277 28.9% 301 28.4% 1.02 0.84 to 1.25
Small vessel occlusion 171 17.8% 149 14.1% 1.26 0.99 to 1.60
Dissections 45 4.7% 30 2.8% 1.61* 1.01 to 2.58
Other determined 38 4.0% 48 4.5% 0.83 0.54 to 1.28
Undetermined mechanism 89 9.3% 93 8.8% 1.01 0.74 to 1.37
Multiple mechanisms 46 4.8% 54 5.1% 0.89 0.60 to 1.34
PFO as likely cause 35 3.6% 36 3.4% 1.03 0.64 to 1.65
Reason: time
Too late intravenous 25 2.6% 26 2.5% 1.04 0.59 to 1.81
Too late intravenous and no indication intra-arterial 127 13.2% 76 7.2% 1.92* 1.42 to 2.59
Too late intravenous and intra-arterial 209 21.8% 209 19.7% 1.10 0.88 to 1.36
Unknown onset 268 27.9% 399 37.6% 0.62* 0.51 to 0.74
Total 629 65.6% 710 67.0% 0.86 0.72 to 1.04
Reason: severity
Too mild 442 46.1% 497 46.9% 0.97 0.82 to 1.16
Too severe 20 2.1% 5 0.5% 4.37* 1.63 to 11.70
Rapid improvement to below threshold 16 1.7% 2 0.2% 8.73* 2.00 to 38.08
Total 478 49.8% 489 46.1% 1.10 0.92 to 1.32
Reason: age
>80 years 183 19.1% 102 9.6% 2.15* 1.66 to 2.79
Reason: imaging
Too large infarct 0 0.0% 32 3.0% 30.24*§, p=0.000
Too little penumbra 6 0.6% 6 0.6% 1.08 0.35 to 3.35
Too large infarct and too little penumbra 0 0.0% 7 0.7% 6.53*¶ , p=0.016
Subacute infarct on imaging 6 0.6% 12 1.1% 0.53 0.20 to 1.43
Other/intracranial haemorrhage 3 0.3% 20 1.9% 0.16* 0.05 to 0.54
Total 15 1.6% 77 7.3% 0.20* 0.11 to 0.34
Reason: high bleeding risk
INR elevated 98 10.2% 76 7.2% 1.43* 1.05 to 1.96
Thrombocytopenia 1 0.1% 5 0.5% 0.21 0.02 to 1.84
Recent intervention 5 0.5% 14 1.3% 0.38 0.14 to 1.06
Previous intracranial haemorrhage 5 0.5% 12 1.1% 0.45 0.16 to 1.27
Intracranial vascular malformation 6 0.6% 8 0.8% 0.81 0.28 to 2.33
Other 3 0.3% 21 2.0% 0.15* 0.04 to 0.51
Full dose heparin or LMWH 5 0.5% 15 1.4% 0.36* 0.13 to 0.98
Total 123 12.8% 151 14.2% 0.86 0.66 to 1.11
Reason: other
No good reason according to hospital recommendations 32 3.3% 25 2.4% 1.39 0.82 to 2.36
Recent stroke 25 2.6% 26 2.5% 1.04 0.59 to 1.81
Stroke uncertain 10 1.0% 48 4.5% 0.22* 0.11 to 0.43
Epileptic seizure 5 0.5% 8 0.8% 0.67 0.22 to 2.06
Comorbidity/dependency 21 2.2% 64 6.0% 0.34* 0.20 to 0.56
Other 13 1.4% 13 1.2% 1.08 0.50 to 2.33
Total 106 11.1% 184 17.4% 0.57* 0.44 to 0.74
Asterisk (*), significant on p<0.05 level. Definitions of reasons for non-thrombolysis see text/table 5.
†TOAST17 classification.
‡Ipsilateral internal carotid stenosis <50%(NASCET)/risk factors for atherosclerotic disease, for details see PERFORM definition.18
§χ2 test.
¶Fisher’s exact test (expected cell frequency <5).
INR, international normalised ratio; LMWH, low molecular weight heparin; NIHSS, National Institute of Health Stroke Scale score; PFO, patent foramen ovale; TOAST, TOAST, Trial of Org
10172 in Acute Stroke Treatment.
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stroke identiﬁcation and patient delivery. However, in patients
arriving early, relative contraindications prevented thrombolysis
in about 20% of otherwise eligible patients.
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